Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | TP53 | P04637 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 14/20 | 0.56 |
| ▸ | NPC1 | O15118 | 10/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669056 | 0.80 | SMN1; SMN2 (0.75) | SMN1; SMN2ALDH1A1TP53HPGDKDM4E | |
| SCHEMBL22493892 | 0.80 | F2R (0.48) | SMN1; SMN2ALDH1A1TP53HPGDKDM4E | |
| SCHEMBL22493874 | 0.77 | TLK2 (0.40) | SMN1; SMN2ALDH1A1TP53KDM4EHSD17B10 | |
| SCHEMBL22493881 | 0.76 | KCNK3 (0.56) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL23011774 | 0.75 | ALDH1A1 (0.84) | SMN1; SMN2ALDH1A1RAB9ANPC1CASP3 | |
| SCHEMBL22493879 | 0.75 | PTPN1 (0.55) | SMN1; SMN2KDM4ERAB9ANPC1PTPN1 | |
| SCHEMBL7743467 | 0.74 | RAB9A (0.75) | SMN1; SMN2ALDH1A1TP53KDM4ERAB9A | |
| SCHEMBL20353548 | 0.74 | LMNA (0.63) | SMN1; SMN2ALDH1A1TP53HPGDKDM4E | |
| SCHEMBL3482802 | 0.74 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1TP53HPGDKDM4E | |
| SCHEMBL3483011 | 0.74 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1TP53HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464289-B1 | ULTRA-POTENT VINCA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBULIN DIMER-DIMER INTERFACE | SCRIPPS RESEARCH INST (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10975101-B2 | Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tublin dimer-dimer interface | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200317696-A1 | ULTRA-POTENT VINA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBLIN DIMER-DIMER INTERFACE | NATIONAL INSTITUTES OF HEALTH | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975101-B2 | Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tublin dimer-dimer interface | TUBA1C, TUBB2A, TUBA1A | SMN1; SMN2 2824/4885ALDH1A1 2428/4885TP53 251/4885 |
| US-20200317696-A1 | ULTRA-POTENT VINA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBLIN DIMER-DIMER INTERFACE | TUBA1A, TUBA1C, TUBB2A | SMN1; SMN2 2867/4885ALDH1A1 2627/4885TP53 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.